BRAND_ANALYSIS #ROCHE HEALTH & PHARMA #22 OF 26 IN HEALTH & PHARMA ALIGNED

Roche

· Private · Updated 22 Nov 2026 07:19 UTC
#1056 of 1208 overall by tension · #22 of 26 in Health & Pharma
9 Aligned
The Balanced
Analysis

Roche comes in at #1056 with cultural 46, business 55 and tension 9, a sober reading for a pharmaceutical giant. Sentiment is 0.00 and no stock movement is recorded, so the scorecard offers no read on pricing, trials or public trust.

IN THE NEWS (93 articles this week)
US FDA approves Roche's oral treatment for advanced breast cancer - Reuters
Roche’s next major breast cancer drug, Wilserdly, secures FDA approval as 4th oral SERD - Fierce Pharma
Roche Secures First U.S. Approval for New Breast-Cancer Pill - WSJ
Cultural Score
46 / 100
Business Score
55 / 100
TENSION▁▁▁▁▁▁▁▁▁▁▁▁▁▁
CULTURAL▄▄▄▄▄▄▄▄▄▄▄▄▄▄
BUSINESS▅▅▅▅▅▅▅▅▅▅▄▄▅▄
Loading...
Wikipedia Momentum 15/40
News Presence 31/35
Search InterestRedistributed to other dimensions
Stock Momentum 0/30
Market Position 0/25
Revenue Growth 0/25
Earnings Health 0/20
Roche's tension is 9. Commerce outpacing culture. sociologyofcapitalism.com/brand/roche
SHARE ON X
EMBED
<iframe src="https://sociologyofcapitalism.com/embed/roche.html" width="320" height="200" frameborder="0"></iframe>